RGNX - REGENXBIO Inc.
43.18 -0.45 (-1.04%)
After hours: 4:11PM EST
| Previous Close | 42.01 |
| Open | 41.70 |
| Bid | 43.58 x 1000 |
| Ask | 43.59 x 1800 |
| Day's Range | 41.70 - 43.77 |
| 52 Week Range | 30.38 - 63.21 |
| Volume | 395,890 |
| Avg. Volume | 546,139 |
| Market Cap | 1.6B |
| Beta (5Y Monthly) | 0.79 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.75 |
| Earnings Date | Feb. 25, 2020 - Mar. 2, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 75.67 |
- Simply Wall St.
We Think REGENXBIO (NASDAQ:RGNX) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
- Thomson Reuters StreetEvents
Edited Transcript of RGNX earnings conference call or presentation 5-Nov-19 9:30pm GMT
Q3 2019 Regenxbio Inc Earnings Call
- Zacks
Regenxbio (RGNX) Reports Q3 Loss, Tops Revenue Estimates
Regenxbio (RGNX) delivered earnings and revenue surprises of -3.30% and 97.18%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Clearside Biomedical Announces Option Exercise by REGENXBIO for Global License for Use of SCS Microinjector™ in AAV Gene Therapy Delivery
“Our recent partnerships with REGENXBIO, Bausch Health, and Aura Biosciences demonstrate the broad applicability of our suprachoroidal space injection platform to potentially treat multiple ocular diseases including wet AMD, uveitic macular edema, and choroidal melanoma. With these collaborations and planned internal research and development efforts, we look forward to continuing to expand our pipeline,” said George Lasezkay, Pharm.D., J.D., Chief Executive Officer of Clearside. “Results from multiple preclinical studies support the potential safety and effectiveness of suprachoroidally administered AAV-based gene therapy, and we are excited to advance our partnership with REGENXBIO,” said Thomas A. Ciulla, M.D., MBA, Chief Medical Officer of Clearside.
- Simply Wall St.
Announcing: REGENXBIO (NASDAQ:RGNX) Stock Increased An Energizing 142% In The Last Three Years
REGENXBIO Inc. (NASDAQ:RGNX) shareholders might be concerned after seeing the share price drop 23% in the last...
- Zacks
Ultragenyx's (RARE) NDA for LC-FAOD Drug Accepted by FDA
Ultragenyx (RARE) announces FDA's acceptance of the NDA for UX007 for the treatment of LC-FAOD.
- Zacks
Wet AMD Space in Focus: New Drug Approvals & Key Advancements
The FDA approval of Novartis' Beovu for wet AMD brings this space to focus. Let us assess the recent key developments in the area.
- Zacks
Ultragenyx Gets FDA Approval for Label Expansion of Crysvita
Ultragenyx (RARE) and partner Kyowa Kirin get FDA approval for the label expansion of Crysvita in pediatric patients with X-linked hypophosphatemia.
- Simply Wall St.
An Intrinsic Calculation For REGENXBIO Inc. (NASDAQ:RGNX) Suggests It's 21% Undervalued
Does the September share price for REGENXBIO Inc. (NASDAQ:RGNX) reflect what it's really worth? Today, we will...
- Zacks
REGENXBIO (RGNX) Catches Eye: Stock Jumps 5.8%
REGENXBIO (RGNX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
- Zacks
Ultragenyx-GeneTx Get Orphan Drug Status for GTX-102 From FDA
The FDA grants Orphan Drug and Rare Pediatric Disease designations to Ultragenyx (RARE) and partner GeneTx Biotherapeutics' GTX-102 for the treatment of Angelman Syndrome.
- Motley Fool
3 Top Biotech Stocks to Buy Right Now
Patent cliffs and pipeline risks are among the reasons these biologic drug specialists are attractively priced today.
- Zacks
Ultragenyx (RARE) Focuses on Pipeline Amid Low Revenues
Ultragenyx (RARE) focuses on the development of pipeline candidates. Being a new commercial company with lower revenues, development or regulatory setbacks could result in higher operating expenses.
- Thomson Reuters StreetEvents
Edited Transcript of RGNX earnings conference call or presentation 7-Aug-19 8:30pm GMT
Q2 2019 Regenxbio Inc Earnings Call
Motley FoolRegenxbio Inc. (RGNX) Q2 2019 Earnings Call Transcript
RGNX earnings call for the period ending June 30, 2019.
- Zacks
Regenxbio (RGNX) Reports Q2 Loss, Misses Revenue Estimates
Regenxbio (RGNX) delivered earnings and revenue surprises of -44.00% and -65.15%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.
Is REGENXBIO Inc.'s (NASDAQ:RGNX) CEO Overpaid Relative To Its Peers?
Ken Mills has been the CEO of REGENXBIO Inc. (NASDAQ:RGNX) since 2009. This report will, first, examine the CEO...
- Zacks
Are Options Traders Betting on a Big Move in REGENXBIO (RGNX) Stock?
Investors need to pay close attention to REGENXBIO (RGNX) stock based on the movements in the options market lately.
- Thomson Reuters StreetEvents
Edited Transcript of RGNX earnings conference call or presentation 7-May-19 8:30pm GMT
Q1 2019 Regenxbio Inc Earnings Call
- Zacks
REGENXBIO (RGNX) Catches Eye: Stock Jumps 7.4%
REGENXBIO (RGNX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
- Motley Fool
Approval of a Game-Changing Gene Therapy for SMA Delivers a Win for Novartis and Regenxbio
A $2.1 million price tag could make Zolgensma a blockbuster medicine for these companies.
Motley FoolRegenxbio Inc. (RGNX) Q1 2019 Earnings Call Transcript
RGNX earnings call for the period ending March 31, 2019.
- Motley Fool
Top Gene-Sequencing Stocks for 2019
These next-generation companies are working on game-changing ways to obtain and profit from genetic insight.
- Simply Wall St.
Did The Underlying Business Drive REGENXBIO's (NASDAQ:RGNX) Lovely 384% Share Price Gain?
We think that it's fair to say that the possibility of finding fantastic multi-year winners is what motivates many investors. Mistakes are inevitable, but a single top stock pick can cover any losses, and so much more. F...
- Zacks
4 Gene Therapy Players Likely to Become Buyout Targets in 2019
Gene therapy continues to be in focus given the recent spate of deals and acquisitions. We highlight four stocks, which have promising gene therapy candidates in their pipeline.
